Back to Journals » OncoTargets and Therapy » Volume 10

Novel agents for the treatment of childhood leukemia: an update

Authors Eryılmaz E, Canpolat C

Received 23 December 2016

Accepted for publication 20 March 2017

Published 4 July 2017 Volume 2017:10 Pages 3299—3306

DOI https://doi.org/10.2147/OTT.S126368

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Jianmin Xu

Ertugrul Eryılmaz,1 Cengiz Canpolat2

1Department of Pediatrics, Division of Pediatric Hematology and Oncology, Acibadem Maslak Hospital, 2Department of Pediatric Hematology and Oncology, Acibadem Kozyatagi Hospital, Acibadem University School of Medicine, Istanbul, Turkey

Abstract: Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.

Keywords: acute lymphoblastic leukemia, acute myeloid leukemia, pediatric leukemia, systemic therapies
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]